Waldenström macroglobulinemia: the mystery of one clinical case

The clinical case of Waldenström macroglobulinemia with peripheral neuropathy of lower extremities is presented. The course of the disease, symptoms, diagnostic pathway and treatment management are described.

References

1. Ghobrial I.M., Witzig T.E. (2004) Waldenstrom macroglobulinemia. Curr. Treat Options Oncol., 5(3): 239–247. DOI: 10.1007/s11864-004-0015-5.
2. Harris N.L., Jaffe E.S., Diebold J. et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. J. Clin. Oncol., 17: 3835–3849.
3. Waldenström J. (1944) Incipient myelomatosis or «essential» hyperglobulinemia with fibrinogenopenia: a new syndrome? Acta Med. Scandinavica, 117: 216–222.
4. Leleu X., Gay J., Roccaro A.M. et al. (2009) Update on therapeutic options in Waldenström macroglobulinemia. Eur. J. Haematol., 82(1): 1–12.
5. Ghobrial I.M., Gertz M.A., Fonseca R. (2003) Waldenstrom macroglobulinaemia. Lancet Oncol., 4: 679–685.
6. Ghobrial I.M. , Fonseca R., Gertz M.A. et al. (2006) Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br. J. Haematol., 133: 158–164.
7. Hunter Z.R., Xu L., Yang G. et al. (2013) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 123(11): 1637–1646. doi: 10.1182/blood-2013-09-525808.
8. Castillo J.J., Moreno D.F., Arbelaez Z.R., Treon S.P. (2019) CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: a systematic review. Exp. Rev. Hematol., 12(10): 873–881.
9. Koshiol J., Gridley G., Engels E. et al. (2008) Chronic immune stimulation and subsequent Waldenström macroglobulinemia. Arch. Int. Med., 168(17): 1903–1909.
10. Kristinsson S., Björkholm M. et al. (2008) Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood, 112: 3052–3056.
11. Royer R., Koshiol J. et al. (2010) Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. Blood, 115: 4464–4471.
12. Baehring J.M., Hochberg E.P., Raje N. et al. (2008) Neurological manifestations of Waldenström macroglobulinemia. Nat. Clin. Pract. Neurol., 4: 547–556.
13. Castillo J.J., Garcia-Sanz R., Hatjiharissi E. et al. (2016) Recommendations for the diagnosis and initial evaluation of patients with Waldenström macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br. J. Haematol., 175(1): 77–86.
14. Sallman D.A., Chaudhury A., Nguyen J. et al. (2021) List. Handbook of Hematologic Malignancies, 2nd еd., 220 р.
15. Castillo J.J., Treon S.P. (2020) Management of Waldenström macroglobulinemia in 2020. Hematology Am. Soc. Hematol. Educ. Program, 1: 372–379.
16. http://www.dec.gov.ua/wp-content/uploads/2019/11/2013_866_ykpmd_limfomy.pdf.